drugset / Trial / NCT06024746
A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)
Phase 3
Recruiting
1500 enrolled
Colorado Prevention Center
Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma · collabSaint Luke's Mid America Heart Institute · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Combination therapy of finerenone plus empagliflozin will be compared to usual care to determine the efficacy and safety of treatment in patients hospitalized with heart failure.
Timeline
- Start
- 2024-07-09
- Primary completion
- 2027-11
- Completion
- 2027-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Empagliflozin | Small molecule | — | Oral |
| Subject | Finerenone | Small molecule | — | Oral |